[Serum adenosine deaminase and its isozyme activity in leukemia and MDS].
We studied the activity of serum adenosine deaminase (ADA) and its isozyme in 36 leukemic patients (16 ANLL, 11 ALL, and 9 CML) and 8 MDS. Isozyme was measured by erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) inhibitory assay. This assay was simple and reliable. The appearance rate of abnormally high ADA value were 81.24% for ANLL, 100% for ALL, 77.8% for CML and 37.5% for MDS. The ADA level became high when MDS turned into overt leukemia. In isozyme pattern, there was a clear difference between ANLL and ALL. The isozyme I/II ratio was significantly higher (p less than 0.001) in ALL than ANLL. Lymphoblastic crisis of CML also had a high isozyme I/II ratio. There was a correlation between isozyme I and absolute number of peripheral blasts in ALL (r = 0.768). When observed time sequentially, ADA and isozyme changed correlatively with the number of blasts counts. Serum ADA and its isozyme are useful parameters both for leukemic diagnosis and treatment.
Ohata
M
M
Department of Clinical Laboratory Medicine, Shizuoka Red Cross Hospital.
Masuda
I
I
Nonaka
K
K
Sugiura
K
K
Uchida
H
H
Mori
T
T
D000243:Adenosine Deaminase / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D004796:Clinical Enzyme Tests; D006801:Humans; D007527:Isoenzymes / Q000097:blood*; D007938:Leukemia / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000201:enzymology*
D014408:Biomarkers, Tumor; D007527:Isoenzymes; D000243:Adenosine Deaminase